Maryam Ghahremani, Rebeca Leon, Eric E Smith, Zahinoor Ismail
{"title":"探索轻度行为障碍与血浆p-tau217之间的关系：对阿尔茨海默病早期检测的意义。","authors":"Maryam Ghahremani, Rebeca Leon, Eric E Smith, Zahinoor Ismail","doi":"10.1002/dad2.70119","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Mild behavioral impairment (MBI), marked by late-onset persistent neuropsychiatric symptoms (NPS), may signal early dementia risk. While MBI is linked to previously established amyloid-beta (Aβ) and tau biomarkers, its association with plasma p-tau217, a promising blood-based biomarker for Alzheimer's disease (AD), remains unexplored. Here, we investigated the association between MBI and plasma p-tau217 in dementia-free individuals from the Alzheimer's Disease Neuroimaging Initiative.</p><p><strong>Methods: </strong>MBI was defined using the Neuropsychiatric Inventory (NPI) data. Linear regression assessed the association between NPS status and continuous p-tau217 levels, while logistic regression modeled the association between NPS status and p-tau217 positivity, using a study-specific cutoff. Models adjusted for age, sex, education, and cognitive diagnosis.</p><p><strong>Results: </strong>Among 101 participants (mean age = 72.0 ± 6.5; 44.6% female), those with MBI had higher plasma p-tau217 levels (<i>β</i> = 36.4%; 95% confidence interval [CI]: 2.2-82.0, <i>p </i>= 0.04) and higher odds of being p-tau217 positive (odds ratio [OR] = 3.06, 95% CI: 1.14-8.70, <i>p</i> = 0.03) than MBI- participants.</p><p><strong>Discussion: </strong>Findings support the role of MBI in AD risk stratification.</p><p><strong>Highlights: </strong>Mild behavioral impairment (MBI) is linked to elevated plasma p-tau217, a specific Alzheimer's disease biomarker.MBI increases the odds of plasma p-tau217 positivity in dementia-free individuals.Findings support MBI as an early indicator for Alzheimer's disease risk.MBI assessment can improve biomarker-based screening and clinical trial efficiency.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 2","pages":"e70119"},"PeriodicalIF":4.0000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12094880/pdf/","citationCount":"0","resultStr":"{\"title\":\"Exploring the association between mild behavioral impairment and plasma p-tau217: Implications for early detection of Alzheimer's disease.\",\"authors\":\"Maryam Ghahremani, Rebeca Leon, Eric E Smith, Zahinoor Ismail\",\"doi\":\"10.1002/dad2.70119\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Mild behavioral impairment (MBI), marked by late-onset persistent neuropsychiatric symptoms (NPS), may signal early dementia risk. While MBI is linked to previously established amyloid-beta (Aβ) and tau biomarkers, its association with plasma p-tau217, a promising blood-based biomarker for Alzheimer's disease (AD), remains unexplored. Here, we investigated the association between MBI and plasma p-tau217 in dementia-free individuals from the Alzheimer's Disease Neuroimaging Initiative.</p><p><strong>Methods: </strong>MBI was defined using the Neuropsychiatric Inventory (NPI) data. Linear regression assessed the association between NPS status and continuous p-tau217 levels, while logistic regression modeled the association between NPS status and p-tau217 positivity, using a study-specific cutoff. Models adjusted for age, sex, education, and cognitive diagnosis.</p><p><strong>Results: </strong>Among 101 participants (mean age = 72.0 ± 6.5; 44.6% female), those with MBI had higher plasma p-tau217 levels (<i>β</i> = 36.4%; 95% confidence interval [CI]: 2.2-82.0, <i>p </i>= 0.04) and higher odds of being p-tau217 positive (odds ratio [OR] = 3.06, 95% CI: 1.14-8.70, <i>p</i> = 0.03) than MBI- participants.</p><p><strong>Discussion: </strong>Findings support the role of MBI in AD risk stratification.</p><p><strong>Highlights: </strong>Mild behavioral impairment (MBI) is linked to elevated plasma p-tau217, a specific Alzheimer's disease biomarker.MBI increases the odds of plasma p-tau217 positivity in dementia-free individuals.Findings support MBI as an early indicator for Alzheimer's disease risk.MBI assessment can improve biomarker-based screening and clinical trial efficiency.</p>\",\"PeriodicalId\":53226,\"journal\":{\"name\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"volume\":\"17 2\",\"pages\":\"e70119\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12094880/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/dad2.70119\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
以迟发性持续性神经精神症状（NPS）为特征的轻度行为障碍（MBI）可能是早期痴呆风险的信号。虽然MBI与先前建立的淀粉样蛋白- β (a β)和tau生物标志物有关，但其与血浆p-tau217（一种有前途的阿尔茨海默病（AD）血液生物标志物）的关联仍未被探索。在这里，我们研究了来自阿尔茨海默病神经影像学倡议的无痴呆个体的MBI和血浆p-tau217之间的关系。方法：采用神经精神量表（NPI）数据对MBI进行定义。线性回归评估NPS状态与连续p-tau217水平之间的关系，而逻辑回归使用研究特定的截止点来模拟NPS状态与p-tau217阳性之间的关系。模型根据年龄、性别、教育程度和认知诊断进行调整。结果：101名参与者(平均年龄= 72.0±6.5；44.6%女性)，MBI患者血浆p-tau217水平较高(β = 36.4%；95%可信区间[CI]: 2.2-82.0, p = 0.04)， p-tau217阳性的几率比MBI组高（比值比[OR] = 3.06, 95% CI: 1.14-8.70, p = 0.03）。讨论：研究结果支持MBI在AD风险分层中的作用。重点：轻度行为障碍（MBI）与血浆p-tau217升高有关，p-tau217是一种特定的阿尔茨海默病生物标志物。MBI增加了无痴呆个体血浆p-tau217阳性的几率。研究结果支持MBI作为阿尔茨海默病风险的早期指标。MBI评估可以提高基于生物标志物的筛选和临床试验效率。
Exploring the association between mild behavioral impairment and plasma p-tau217: Implications for early detection of Alzheimer's disease.
Introduction: Mild behavioral impairment (MBI), marked by late-onset persistent neuropsychiatric symptoms (NPS), may signal early dementia risk. While MBI is linked to previously established amyloid-beta (Aβ) and tau biomarkers, its association with plasma p-tau217, a promising blood-based biomarker for Alzheimer's disease (AD), remains unexplored. Here, we investigated the association between MBI and plasma p-tau217 in dementia-free individuals from the Alzheimer's Disease Neuroimaging Initiative.
Methods: MBI was defined using the Neuropsychiatric Inventory (NPI) data. Linear regression assessed the association between NPS status and continuous p-tau217 levels, while logistic regression modeled the association between NPS status and p-tau217 positivity, using a study-specific cutoff. Models adjusted for age, sex, education, and cognitive diagnosis.
Results: Among 101 participants (mean age = 72.0 ± 6.5; 44.6% female), those with MBI had higher plasma p-tau217 levels (β = 36.4%; 95% confidence interval [CI]: 2.2-82.0, p = 0.04) and higher odds of being p-tau217 positive (odds ratio [OR] = 3.06, 95% CI: 1.14-8.70, p = 0.03) than MBI- participants.
Discussion: Findings support the role of MBI in AD risk stratification.
Highlights: Mild behavioral impairment (MBI) is linked to elevated plasma p-tau217, a specific Alzheimer's disease biomarker.MBI increases the odds of plasma p-tau217 positivity in dementia-free individuals.Findings support MBI as an early indicator for Alzheimer's disease risk.MBI assessment can improve biomarker-based screening and clinical trial efficiency.
期刊介绍：
Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
